# Children with ADHD and EEG abnormalities at baseline assessment, risk of epileptic seizures and maintenance on methylphenidate three years later

**Authors:** Dobrinko Socanski, Geir Ogrim, Nezla Duric

PMC · DOI: 10.1186/s12991-024-00510-4 · 2024-06-21

## TL;DR

This study found that ADHD children with EEG abnormalities did not have a higher risk of seizures or lower methylphenidate use after three years.

## Contribution

The study provides new insights into the long-term outcomes of ADHD children with EEG abnormalities and methylphenidate use.

## Key findings

- EEG abnormalities were found in 52.8% of ADHD children.
- No significant difference in methylphenidate maintenance was observed between groups with and without epileptiform EEG abnormalities.
- Children with drug-resistant epilepsy experienced seizures, but frequency did not increase.

## Abstract

This study aimed to assess the incidence of EEG abnormalities (EEG-ab) in children diagnosed with ADHD, investigate the risk of epileptic seizures (SZ) and maintenance on methylphenidate (MPH) over a three-year period.

A total of 517 ADHD children aged 6–14 years were included. Baseline assessments included the identification of EEG-ab, ADHD inattentive subtype (ADHD-I), comorbid epilepsy, the use of antiepileptic drugs (AEDs) and the use of MPH. At the 3-year follow-up, assessments included the presence of EEG-ab, maintenance on MPH, AED usage, SZ risk in cases with EEG-epileptiform abnormalities (EEG-epi-ab), compared with control ADHD cases without EEG-epi-ab matched for age and gender.

EEG-ab were identified in 273 (52.8%) cases. No statistically significant differences were observed between the EEG-ab and EEG-non-ab groups in terms of age, gender, ADHD-I type or initial use of MPH. EEG non-epileptiform abnormalities (EEG-non-epi-ab) were found in 234 out of 478 (49%) cases without EEG-epi-ab. Notably, EEG-non-epi-ab occurred more frequently in the group of 39 cases with EEG-epi-ab (30/39 (76.9%) vs. 9/39, (21.3%), a subset selected for 3-year follow-up. At 3-year-follow-up no statistically significant difference was found in maintenance on MPH in ADHD cases with and without EEG-epi-ab. Nobody of ADHD cases without comorbid epilepsy or with comorbid epilepsy with achieved SZ freedom developed new SZ. Only 3 children with drug resistant epilepsy experienced SZs, without increase in SZ frequency. The disappearance rate of EEG-epi-ab was higher than that EEG-non-epi-ab (71.8% vs. 33.3%).

Children with and without EEG-ab exhibited similar patterns of MPH use (initial use, positive response, and maintenance on MPH). The presence of comorbid epilepsy and EEG-ab, with or without EEG-epi-ab, was not associated with an increased risk of SZ despite the use of MPH.

## Linked entities

- **Chemicals:** methylphenidate (PubChem CID 4158)
- **Diseases:** ADHD (MONDO:0007743), epilepsy (MONDO:0005027)

## Full-text entities

- **Diseases:** drug resistant epilepsy (MESH:D000069279), EEG abnormalities (MESH:D000014), ADHD (MESH:D001289), epileptiform abnormalities (MESH:D014277), epilepsy (MESH:D004827), SZ (MESH:D012640)
- **Chemicals:** MPH (MESH:D008774)

---
Source: https://tomesphere.com/paper/PMC11193234